Autopsy report · NCT05601492

Adherence to Otezla

“Terminated IRB approval 6/26/2024, study was never initiated or activated”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Early Phase 1

Sponsor

Wake Forest University Health Sciences

Sponsor type

University, hospital or other

Conditions

Psoriasis

Interventions

Otezla - Standard Care; Reminder Text Intervention with apremilast; Extended Consultation for apremilast

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Simvastatin Nasal Rinses for the Treatment of COVID-19 Mediated Dysomsia
  “Study halted prematurely; IRB approval not obtained” (89% match in meaning)
• Low-Level Transcutaneous Vagus Stimulation in ST Segment Elevation Myocardial Infarction: TREAT MI Study
  “Study never initiated; withdrawn prior to receiving IRB approval” (87% match in meaning)
• Safety of Topical Tranexamic Acid in Total Joint Arthroplasty in High Risk Patients
  “Study did not receive IRB approval, so did not start” (86% match in meaning)
• Study Comparing Intubation Via Video Laryngeal Mask Airways (VLMAs) Versus Video Laryngoscopy
  “Study never approved by the IRB. Was not initiated” (86% match in meaning)
• Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux
  “IRB approval not renewed/approval lapsed. Prior status: insufficient enrollment; study suspended pending analysis” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.